Clinical Trial

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.
Protocol Amendment History 5 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-17
notable Primary completion pushed: 2026-07 -> 2026-08 2026-06-17
minor Completion pushed: 2026-07 -> 2026-08 2026-06-17
notable Primary completion pushed: 2026-04 -> 2026-07 2026-04-18
minor Completion pushed: 2026-04 -> 2026-07 2026-04-18
Trial Details
NCT Number NCT06945419
Lead Sponsor Eli Lilly and Company
Conditions Healthy, Overweight, Obesity, Type 2 Diabetes
Enrollment 216 participants
Start Date 2025-04-23
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-16